| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $69.5M | +38.2% |
| SG&A Expense | $20.3M | +17.8% |
| Operating Income | -$89.8M | -33.5% |
| Income Tax | $0 | — |
| Net Income | -$83.9M | -28.3% |
| EPS (Basic) | -$3.43 | +41.0% |
| EPS (Diluted) | -$3.43 | +41.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $26.7M | -33.6% |
| Short-term Investments | $81.3M | -44.0% |
| Current Assets | $112.7M | -40.3% |
| Total Assets | $130.9M | -37.5% |
| Current Liabilities | $13.1M | +6.8% |
| Total Liabilities | $21.0M | -8.6% |
| Stockholders' Equity | $110.0M | -41.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$76.8M | -39.5% |
| Capital Expenditures | $2.6M | +303.0% |
| Investing Cash Flow | $63.4M | +152.6% |
| Financing Cash Flow | $9K | -100.0% |
| Free Cash Flow | -$79.3M | -42.5% |